Psychiatr. pro Praxi, 2005; 2: 80-82

ANTIPSYCHOTIC DRUGS - A RISK FACTOR FOR VENOUS THROMBOEMBOLISM?

MUDr. Jiří Masopust1, MUDr. Ing. Aleš Urban1, MUDr. Radovan Malý Ph.D2
1 Psychiatrická klinika LF UK a FN Hradec Králové
2 I. interní klinika Fakultní nemocnice v Hradci Králové

A treatment with antipsychotic drugs is associated with an increased risk of a venous thrombosis. The biological mechanism responsible for this possible adverse drug reaction is unknown, but the number of explaining hypotheses is growing. Some abnormalities of coagulation or a stasis of blood flow are considered. The influence of the life-style of patients with the long-term antipsychotic therapy can’t be neglected. In most cases, there are additional risk factors. Double-blind studies still failed to prove a possible connection between an increased risk of a venous thromboembolism and the treatment with antipsychotics drugs as yet. We present case-reports related to this topic.

Keywords: Key words: antipsychotics, venous thrombosis, pulmonary embolism, antiphospholipids antibodies.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J, Urban A, Malý R. ANTIPSYCHOTIC DRUGS - A RISK FACTOR FOR VENOUS THROMBOEMBOLISM? Psychiatr. praxi. 2005;9(2):80-82.
Download citation

References

  1. Canoso RT, Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990 15; 27: 863-870. Go to original source... Go to PubMed...
  2. Firer M, Sirota P, Schild K, Elizur A, Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994; 14: 73-78. Go to original source... Go to PubMed...
  3. Grahmann H, Suchenwirth R. Thrombose hazard in chlorpromazine and reserpine therapy of endogenous psychosis. Nervenarzt 1959; 30: 224-225. Go to PubMed...
  4. Grohmann R, Rüther E, Engel RR, Hippius H. Assessment of adverse drug reactions in psychiatric inpatiens with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32: 21-28. Go to original source... Go to PubMed...
  5. Hägg S, Spigset O, Söderström TG. Association of venous tromboembolism and clozapine. Lancet 2000; 355: 1155-1156. Go to original source... Go to PubMed...
  6. Hägg S, Spigset O. Antipsychotic-induced venous tromboembolism: a review of the evidence. CNS Drugs 2002; 16: 765-776. Go to original source... Go to PubMed...
  7. Hägg S, et al. Olanzapine nad venous thromboembolism. Int Clin Psychopharmacol 2003; 18: 299-300. Go to original source... Go to PubMed...
  8. Herrmann N, Mamdani M, Lanctot KL. Atypical Antipsychotic and Risk of Cerebrovascular Accidents. Am J Psychiatry 2004; 161: 1113-1115. Go to original source... Go to PubMed...
  9. Hummer M, Huber J. Hyperprolactinemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 89-197. Go to original source... Go to PubMed...
  10. Kamijo Y, et al. Acute massive pulmonary thromboembolism associated with risperidone nad convetional phenothiazines. Circ J 2003; 67: 46-48. Go to original source... Go to PubMed...
  11. Kortepeter C, Chen M, Knudsen JF, Dubitsky GM, Ahmad SR, Beitz J. Clozapine and venous thromboembolism. Am J Psychiatry 2002; 159: 876-877. Go to original source... Go to PubMed...
  12. Meier-Ewert K, Baumgart HH, Friedeberg P. Tromboembolische Komplikationen bei neuro- und thymoleptischer Behandlung. Deutsche medizinische Wochenschrift 1967; 92: 2174-2178. Go to original source... Go to PubMed...
  13. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and risk of venous thromboembolism. Thromb Haemost 2002; 88: 205-209. Go to original source... Go to PubMed...
  14. Rosack J. Antipsychotic Do Not Appear To increase Stroke Risk. Psychiatric News 2004; 39: 22. Go to original source...
  15. Thomassen R, Vanderbroucke JP, Rosendaal FR. Antipsychotics medication and venous thrombosis. Br J Psychiatry 2001; 179: 63-66. Go to original source... Go to PubMed...
  16. Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340: 1067-1068. Go to original source... Go to PubMed...
  17. Vargas-Alarcon G, Yamamoto-Furusho JK, Zuniga J, Canoso R, Granados J. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). J Autoimmun. 1997; 10: 579-83. Go to original source... Go to PubMed...
  18. Wallaschofski H et al. Hyperprolactinemia in patients on antipsychotics drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychofarmacol 2003; 23: 479-483. Go to original source... Go to PubMed...
  19. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677. Go to original source... Go to PubMed...
  20. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, Severiny and consequences. British Journal of Psychiatry 2003; 182: 199-204. Go to original source... Go to PubMed...
  21. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167: 1269-1270. Go to PubMed...
  22. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395. Go to original source... Go to PubMed...
  23. Zornberg GI, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case control study. Lancet 2000; 356: 1219-1223. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.